<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00324311</url>
  </required_header>
  <id_info>
    <org_study_id>MW2004-11-02</org_study_id>
    <nct_id>NCT00324311</nct_id>
  </id_info>
  <brief_title>Enzymatic Debridement in Burns Patients: A Comparison to Standard of Care</brief_title>
  <official_title>Enzymatic Debridement in Burns Patients (Children &amp; Adults): A Comparison to Standard of Care (Protocol MW 2004-11-02)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MediWound Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>MediWound Ltd</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Burns represent one of the most severe and dreaded traumas. Burned and traumatized tissue is
      known as eschar. The dead eschar, if not removed, often becomes heavily contaminated and is
      the source of local and/or systemic infection or sepsis. The local inflammation and infection
      destroy healthy surrounding tissues and extends the original damage. In order to prevent
      these complications, and in order to minimize the risk of infection, it is imperative to
      evaluate the burn and remove all of the offending eschar at the earliest possible
      opportunity. This removal of dead tissue is termed &quot;debridement&quot;.

      The most direct debridement method for eschar removal is surgery. Traditional, conservative
      non-surgical debridement is a lengthy process which often involves many complications.

      The objective of this study is to evaluate the safety and enzymatic debriding efficacy of
      Debrase Gel Dressing (DGD) in hospitalized patients with deep partial thickness and/or full
      thickness thermal burns and to compare DGD to standard of care (SOC).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Completed study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2005</start_date>
  <completion_date type="Actual">February 2010</completion_date>
  <primary_completion_date type="Actual">October 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Co-primary: % treated wound excised (by tangential/minor/Versajet excision) or dermabrasion, in first surgery, of deep partial wounds</measure>
    <time_frame>Surgical excision/dermabrasion performed as initial debridement (surgical SOC group) or as first post-debridement procedure (DGD or non-surgical SOC groups)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Co-primary: % treated wound autografted of deep partial wounds</measure>
    <time_frame>Post-debridement autografts</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>% treated wound excised (by tangential/minor/Versajet excision) or dermabrasion, in first surgery, for all wounds</measure>
    <time_frame>As for primary endpoint</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to complete wound closure</measure>
    <time_frame>% epithelialization assessed post-debridement at weekly intervals until all a patient's wounds closed</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Timely eschar removal</measure>
    <time_frame>Debridement procedures</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood loss</measure>
    <time_frame>Throughout study</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">182</enrollment>
  <condition>Burn</condition>
  <arm_group>
    <arm_group_label>DGD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>SOC</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DGD</intervention_name>
    <description>Lyophilized, sterile mixture of proteolyzed enzymes; mixed with gel,for topical application.</description>
    <arm_group_label>DGD</arm_group_label>
    <arm_group_label>SOC</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Males and females between 4 years to 55 years of age,

          2. Thermal burns caused by fire/flame, scalds or contact,

          3. Deep partial thickness (mixed deep dermal) and/or full thickness (3°) burn wounds ≥ 5%
             and ≤ 30% Total Body Surface Area (TBSA); all these wounds must receive study
             treatment,

          4. At least one wound of ≥ 2% TBSA deep partial thickness and/or full thickness burn,

          5. Total burn wounds ≤ 30% TBSA,

          6. Signed written informed consent.

        Exclusion Criteria:

          1. Deep partial thickness and/or full thickness facial burn wounds, &gt; 0.5% TBSA; study
             treatment of facial burns is not allowed,

          2. Study treatment of perineal and/or genital burns (A patient with these wounds may be
             enrolled but the wounds may not be designated as target wounds),

          3. Circumferential anterior/posterior trunk full thickness fire/flame burns, &gt; 15% TBSA,
             (Circumferential is defined as encircling ≥ 80% of the trunk circumference.)

          4. Pre-enrollment escharotomy,

          5. Heavily contaminated burns or pre-existing infections,

          6. Signs that may indicate smoke inhalation,

          7. General condition of patient would contraindicate surgery,

          8. Pregnant women (positive pregnancy test) or nursing mothers,

          9. Poorly controlled diabetes mellitus (HbA1c&gt;9%),

         10. Cardio-pulmonary disease (MI within 4 weeks prior to injury, pulmonary hypertension,
             COPD or pre-existing oxygen-dependent pulmonary diseases),

         11. Pre-existing diseases which interfere with circulation (PVD, edema, lymphedema,
             surgery to the regional lymph nodes, obesity, varicose veins),

         12. Immediate life threatening conditions (such as immuno-compromising diseases, life
             threatening trauma, severe pre-existing coagulation disorder, cardiovascular, liver or
             neoplastic disease),
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>4 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lior Rosenberg, MD</last_name>
    <role>Study Chair</role>
    <affiliation>MediWound Ltd</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Royal Hospital Perth</name>
      <address>
        <city>Perth</city>
        <state>Western Australia</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pronto Socorro para Queimaduras de Goiania</name>
      <address>
        <city>Goiania</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital do Servidor Publico do Estado de Sao Paulo</name>
      <address>
        <city>Sao Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Regional et Universitaire de Marseille, Service de Chirurgie Plastique Reparatrice et Esthetique</name>
      <address>
        <city>Marseille</city>
        <zip>13005</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center Des Brules Hopital Cochin</name>
      <address>
        <city>Paris</city>
        <zip>F-75014</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Unfallkrankenhaus Berlin Burn Center</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BG - Unfallklinik Ludwigshafen</name>
      <address>
        <city>Ludwigshafen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Mannheim Universtatsklinikum</name>
      <address>
        <city>Mannheim</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Soroka University Medical Center</name>
      <address>
        <city>Beer Sheba</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Grandi Ustionati</name>
      <address>
        <city>Cesena</city>
        <zip>47023</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Direttore U.O. Chirurgia Plastica e Centro Ustioni Ospedale Civico</name>
      <address>
        <city>Palermo</city>
        <zip>90127</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wojskowy Instytut Medyczny</name>
      <address>
        <city>Warsaw</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emergency Clinic Hospital &quot;Bagdazar-Arsenie&quot;</name>
      <address>
        <city>Bucharest</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Burns &amp; Reconstructive Surgery, University Hopsital Bratislava</name>
      <address>
        <city>Bratislava</city>
        <zip>82107</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinic of Burns and Reconstructive Surgery Hospital Kosice</name>
      <address>
        <city>Kosice-Saca</city>
        <zip>04015</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Queen Victoria Hospital</name>
      <address>
        <city>East Grinstead</city>
        <zip>RH19 3DZ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Burn Center Pinderfields Hospital</name>
      <address>
        <city>Wakefield</city>
        <zip>WF1 4EE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Brazil</country>
    <country>France</country>
    <country>Germany</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>Slovakia</country>
    <country>United Kingdom</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
    <country>Netherlands</country>
    <country>Portugal</country>
  </removed_countries>
  <reference>
    <citation>Rosenberg L, Lapid O, Bogdanov-Berezovsky A, Glesinger R, Krieger Y, Silberstein E, Sagi A, Judkins K, Singer AJ. Safety and efficacy of a proteolytic enzyme for enzymatic burn debridement: a preliminary report. Burns. 2004 Dec;30(8):843-50.</citation>
    <PMID>15555800</PMID>
  </reference>
  <verification_date>July 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 10, 2006</study_first_submitted>
  <study_first_submitted_qc>May 10, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 11, 2006</study_first_posted>
  <last_update_submitted>May 8, 2011</last_update_submitted>
  <last_update_submitted_qc>May 8, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 10, 2011</last_update_posted>
  <responsible_party>
    <name_title>Siyu Liu, Vice President, North American Innovative Research &amp; Development and Head of Global Clinical Operations )</name_title>
    <organization>Teva Neuroscience</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Burns</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

